Core Insights - ClearBridge Investments reported a strong rebound in U.S. equities during Q2 2025, with the S&P 500 Index returning 10.9% and the Russell 3000 Index advancing 11.0% as risk-on sentiment increased following a pause in tariff implementation [1] - The ClearBridge Select Strategy outperformed its benchmark due to effective portfolio construction across various companies and sectors with distinct growth drivers [1] Company Highlights - Caris Life Sciences, Inc. (NASDAQ:CAI) is highlighted as a key stock in the ClearBridge Select Strategy, being an AI-driven TechBio company focused on cancer care and genetic profiling [2][3] - Caris Life Sciences experienced a one-month return of -12.04% but gained 19.75% over three months, closing at $33.53 per share with a market capitalization of $9.431 billion as of September 17, 2025 [2] - The company went public late in Q2 2025 and offers differentiated molecular profiling services to biopharmaceutical companies using machine learning algorithms [3] Hedge Fund Interest - Caris Life Sciences was held by 42 hedge fund portfolios at the end of Q2 2025, a significant increase from 0 in the previous quarter, indicating growing interest among institutional investors [4] - Despite the potential of Caris Life Sciences, the company is not listed among the 30 most popular stocks among hedge funds, with some analysts suggesting that other AI stocks may offer greater upside potential and less downside risk [4]